Fig. 3From: Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and cystic mouse Pkd2 model gene expression reversionFDA-Approved Drug Candidates MOA and Original Indications from Pre-Cystic Signature Reversion. A The most frequent MOA of all FDA-approved candidates. B The most frequent disease areas for original indications of candidates, and (C) alluvial plot of the top FDA approved candidates by NCS and their MOA, with drugs that have been previously explored for PKD treatment marked with red arrows, and drugs previously explored for CKD and/or AKI are marked with dark purple arrowsBack to article page